New Bolton Center Kennett Square, PA
Emergencies & Appointments:
Ryan Hospital Philadelphia, PA

Desmopressin (DDAVP) for Dogs with suspected Mammary Carcinoma

May 26, 2015

The VCIC is now enrolling dogs with mammary tumors for a clinical trial assessing the safety, efficacy, and tolerability of two subcutaneous administrations of Desmopressin (DDAVP) in dogs with mammary carcinoma. This study could potentially provide a prolonged survival time and delay the onset of metastasis (spread of cancer) to the lungs in dogs with mammary carcinoma.

 All study participants will be randomized to receive either an injection of DDAVP or placebo for their two injections. Eligibility requires surgery (mastectomy) be performed at PennVet. Following a confirmed diagnosis of mammary carcinoma, dogs will be required to make trips every 4 months to PennVet for x-rays of the chest to look for metastasis.

Costs associated with surgery, histopathology (biopsy), lab work, and follow up study visits will be covered by the study only for canines diagnosed with mammary carcinoma. If the canine does not have mammary carcinoma, all costs will be the owner's responsibility. All enrolled patients must not pursue any other treatments for mammary carcinoma, including chemotherapy, during their participation in the clinical trial.

Eligibility Criteria:

  • Dogs with mammary carcinoma tumors more than 3 cm (1.5 inches) in size
  • Willing to have mastectomy performed at PennVet
  • Histological diagnosis of mammary carcinoma
  • Willing to allow two injections of DDAVP/placebo pre and post-operatively
  • Willing to follow up with radiographs (x-rays) every 4 months for up to a year, and then every 6 months until metastasis in lungs develops, or until death


  • Financial coverage for surgery, blood work, urinalysis, histopathology, imaging (x-rays), and oncology examinations (only applies to canines diagnosed with mammary carcinoma)


If interested in enrolling your dog in this study, or would like to learn more, contact the VCIC at 215-573-0302 or email for more information about this or any of our other studies.